Agile Therapeutics, Inc. (AGRX) At $2.76 Forms Top; Navigant Consulting (NCI)’s Sentiment Is 1.31

Navigant Consulting, Inc. provides professional services to corporate executives and senior management, corporate counsel, law firms, corporate boards, special committees, and governmental agencies worldwide. The company has market cap of $897.73 million. The firm operates through four divisions: Healthcare; Energy; Financial Services Advisory and Compliance; and Disputes, Forensics & Legal Technology. It has a 20.8 P/E ratio. The Healthcare segment provides consulting and business process management services to healthcare providers, payers, and life sciences companies.

Agile Therapeutics, Inc. (AGRX) formed multiple top with $2.87 target or 4.00% above today’s $2.76 share price. Agile Therapeutics, Inc. (AGRX) has $94.35M valuation. The stock decreased 2.82% or $0.08 during the last trading session, reaching $2.76. About 731,190 shares traded or 50.48% up from the average. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 48.71% since December 29, 2016 and is downtrending. It has underperformed by 65.41% the S&P500.

The stock increased 0.51% or $0.1 during the last trading session, reaching $19.55. About 276,452 shares traded. Navigant Consulting, Inc. (NCI) has risen 27.76% since December 29, 2016 and is uptrending. It has outperformed by 11.06% the S&P500.

Tieton Capital Management Llc holds 3.51% of its portfolio in Navigant Consulting, Inc. for 241,094 shares. Tributary Capital Management Llc owns 1.07 million shares or 1.55% of their US portfolio. Moreover, Dalton Greiner Hartman Maher & Co has 1% invested in the company for 1.06 million shares. The Oregon-based Northwest Investment Counselors Llc has invested 0.3% in the stock. Nj State Employees Deferred Compensation Plan, a New Jersey-based fund reported 55,000 shares.

Since January 1, 0001, it had 0 insider purchases, and 1 insider sale for $206,920 activity.

Analysts await Navigant Consulting, Inc. (NYSE:NCI) to report earnings on February, 15. They expect $0.40 EPS, up 33.33% or $0.10 from last year’s $0.3 per share. NCI’s profit will be $18.37M for 12.22 P/E if the $0.40 EPS becomes a reality. After $0.30 actual EPS reported by Navigant Consulting, Inc. for the previous quarter, Wall Street now forecasts 33.33% EPS growth.

Among 6 analysts covering Agile Therapeutics (NASDAQ:AGRX), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Agile Therapeutics had 21 analyst reports since December 30, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Agile Therapeutics, Inc. (NASDAQ:AGRX) rating on Tuesday, October 10. Cantor Fitzgerald has “Buy” rating and $8.0 target. The company was downgraded on Tuesday, December 26 by William Blair. On Tuesday, June 27 the stock rating was maintained by Noble Financial with “Buy”. On Monday, October 2 the stock rating was reinitiated by H.C. Wainwright with “Buy”. The company was maintained on Friday, July 28 by H.C. Wainwright. The firm has “Buy” rating given on Monday, June 12 by Noble Financial. Cantor Fitzgerald maintained Agile Therapeutics, Inc. (NASDAQ:AGRX) on Monday, November 6 with “Buy” rating. The stock of Agile Therapeutics, Inc. (NASDAQ:AGRX) has “Buy” rating given on Thursday, November 9 by Noble Financial. The stock of Agile Therapeutics, Inc. (NASDAQ:AGRX) earned “Hold” rating by Janney Capital on Friday, December 22. RBC Capital Markets maintained it with “Buy” rating and $800 target in Friday, July 14 report.